跳至主要内容
临床试验/ACTRN12608000388314
ACTRN12608000388314进行中(未招募)2 期

Safety and efficacy of Neurotec in reducing pain in patients with diabetic neuropathy - a single armed phase II trial

Tehran University of Medical Sciences0 个研究点目标入组 10 人开始时间: 2008年8月4日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • having diabetic I or II
  • having pain and paresthesia interfering with every day activities
  • Diminished anckle reflex
  • Abnormal 128 Hz vibration test

排除标准

  • Unwilling to sign a written consent
  • Non-diabetic neuropathy
  • Wound infection or infection in extremities
  • ischaemic heart disease
  • Heart failure
  • reeiving immunosuppresive drugs, corticosteroids, chemotherapy, radiotherapy
  • Alcohol and substance misuse
  • Electrolyte disturbances
  • History of known hypersensitivity to drugs
  • Haemodialysis

研究者

相似试验